North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma-Reference-Cited by-同舟云学术

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma

Published:2017-05-10 Issue:18 Volume:123 Page:3494-3501
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

McWilliams Robert R.¹^ORCID,Foster Nathan R.²,Mahoney Michelle R.²,Smyrk Thomas C.³,Murray Joseph A.⁴,Ames Matthew M.⁵,Horvath L. Elise⁶,Schneider Daniel J.⁷,Hobday Timothy J.¹,Jatoi Aminah¹^ORCID,Meyers Jeffrey P.²,Goetz Matthew P.¹

Affiliation:

1. Division of Medical Oncology; Mayo Clinic; Rochester Minnesota

2. Alliance Statistics and Data Center; Mayo Clinic; Rochester Minnesota

3. Division of Anatomic Pathology; Mayo Clinic; Rochester Minnesota

4. Division of Gastroenterology; Mayo Clinic; Rochester Minnesota

5. Division of Pharmacology; Mayo Clinic; Rochester Minnesota

6. Alliance for Clinical Trials in Oncology; Chicago Illinois

7. Metro-Minnesota Community Oncology Research Consortium; Saint Paul Minnesota

Funder

National Institutes of Health

Publisher

Wiley